Huaibing He
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Neuropeptides and Animal Physiology, Peptidase Inhibition and Analysis, Pancreatic function and diabetes, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2004)814 cited
- → Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes(2005)490 cited
- → Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy(2017)331 cited
- → Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes(2014)167 cited
- → A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors(2021)140 cited
- → (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2006)121 cited
- → Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors(2008)106 cited
- → Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes(2017)102 cited
- → Substituted piperazines as novel dipeptidyl peptidase IV inhibitors(2004)97 cited
- → Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors(2004)76 cited